Immunotherapeutic strategies to combat staphylococcal infections

International Journal of Medical Microbiology

Volumn 300, Issue 6, 2010, Pages 402-410

  Ohlsen, Knut ^a   Lorenz, Udo ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Immunotherapy; MRSA; New targets; Staphylococcus aureus; Vaccine

Indexed keywords

2 MERCAPTOPROPIONYLCYSTEINE; ABC TRANSPORTER; ALTASTAPH; ANTIBODY; ANTIINFECTIVE AGENT; AUROGRAB; AUTOINDUCER PEPTIDE 4 MONOCLONAL ANTIBODY; BACTERIAL PROTEIN; CLUMPING FACTOR A ANTIBODY; CNA PROTEIN; COLLAGEN BINDING PROTEIN; DNA VACCINE; ETI 211; FIBRONECTIN BINDING PROTEIN A ANTIBODY; HLA MONOCLONAL ANTIBODY; IMMUNOGLOBULIN CLASS; LIPOTEICHOIC ACID; MICROBIAL SURFACE COMPONENTS RECOGNIZING ADHESIVE MATRIX MOLECULE; PAGIBAXIMAB; PAGIMAXIMAB; PANTON VALENTINE LEUKOCIDIN; PENTASTAPH; POLY N ACETYLGLUCOSAMINE ANTIBODY; POLYCLONAL ANTIBODY; STAPHYLOCOCCAL ENTEROTOXIN B ANTIBODY; STAPHYLOCOCCUS VACCINE; TEFIBAZUMAB; TEICHOIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 710; VANCOMYCIN; VERONATE;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL COLONIZATION; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; BIOFILM; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG BINDING; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PASSIVE IMMUNIZATION; PROSTHESIS INFECTION; QUORUM SENSING; RISK FACTOR; SHORT SURVEY; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTIBODIES, BACTERIAL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS;

EID: 77955554696     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2010.04.015     Document Type: Short Survey

References (75)

1. Arrecubieta C., Matsunaga I., Asai T., Naka Y., Deng M.C., Lowy F.D. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J. Infect. Dis. 2008, 198:571-575.
2. Atkins K.L., Burman J.D., Chamberlain E.S., Cooper J.E., Poutrel B., Bagby S., Jenkins A.T., Feil E.J., van den Elsen J.M. S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. Mol. Immunol. 2008, 45:1600-1611.
3. Benjamin D.K., Schelonka R., White R., Holley H.P., Bifano E., Cummings J., Adcock K., Kaufman D., Puppala B., Riedel P., Hall B., White J., Cotton C.M. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J. Perinatol. 2006, 26:290-295.
4. Brown E.L., Dumitrescu O., Thomas D., Badiou C., Koers E.M., Choudhury P., Vazquez V., Etienne J., Lina G., Vandenesch F., Bowden M.G. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin. Microbiol. Infect. 2009, 15:156-164.
5. Bubeck Wardenburg J., Patel R.J., Schneewind O. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect. Immun. 2007, 75:1040-1044.
6. Bubeck Wardenburg J., Palazzolo-Ballance A.M., Otto M., Schneewind O., DeLeo F.R. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J. Infect. Dis. 2008, 198:1166-1170.
7. Bubeck Wardenburg J., Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 2008, 205:287-294.
8. Burlak C., Hammer C.H., Robinson M.A., Whitney A.R., McGavin M.J., Kreiswirth B.N., Deleo F.R. Global analysis of community-associated methicillin-resistant Staphylococcus aureus exoproteins reveals molecules produced in vitro and during infection. Cell. Microbiol. 2007, 9:1172-1190.
9. Burnie J.P., Matthews R.C., Carter T., Beaulieu E., Donohoe M., Chapman C., Williamson P., Hodgetts S.J. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect. Immun. 2000, 68:3200-3209.
10. Chambers H.F. Community-associated MRSA-resistance and virulence converge. N. Engl. J. Med. 2005, 352:1485-1487.
11. Cheng A.G., Kim H.K., Burts M.L., Krausz T., Schneewind O., Missiakas D.M. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J. 2009, 23:3393-3404. [Erratum in: FASEB J. (2010), 24, 648].
12. Clarke S.R., Brummell K.J., Horsburgh M.J., McDowell P.W., Mohamad S.A., Stapleton M.R., Acevedo J., Read R.C., Day N.P., Peacock S.J., Mond J.J., Kokai-Kun J.F., Foster S.J. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis. 2006, 193:1098-1108.
13. DeJonge M., Burchfield D., Bloom B., Duenas M., Walker W., Polak M., Jung E., Millard D., Schelonka R., Eyal F., Morris A., Kapik B., Roberson D., Kesler K., Patti J., Hetherington S. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr. 2007, 151:260-265. 265 e261.
14. Diep B.A., Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol. 2008, 16:361-369.
15. Diep B.A., Palazzolo-Ballance A.M., Tattevin P., Basuino L., Braughton K.R., Whitney A.R., Chen L., Kreiswirth B.N., Otto M., DeLeo F.R., Chambers H.F. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One 2008, 3:e3198.
16. Dinges M.M., Orwin P.M., Schlievert P.M. Exotoxins of Staphylococcus aureus. Clin. Microbiol. Rev. 2000, 13:16-34.
17. Dryla A., Prustomersky S., Gelbmann D., Hanner M., Bettinger E., Kocsis B., Kustos T., Henics T., Meinke A., Nagy E. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin. Diagn. Lab. Immunol. 2005, 12:387-398.
18. Etz H., Minh D.B., Henics T., Dryla A., Winkler B., Triska C., Boyd A.P., Söllner J., Schmidt W., von Ahsen U., Buschle M., Gill S.R., Kolonay J., Khalak H., Fraser C.M., von Gabain A., Nagy E., Meinke A. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:6573-6578.
19. Fattom A.I., Sarwar J., Ortiz A., Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 1996, 64:1659-1665.
20. Flock J.I., Brennan F. Antibodies that block adherence of to fibronectin. Trends Microbiol. 1999, 7:140-141.
21. Foster T.J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 2005, 3:948-958.
22. Garmory H.S., Titball R.W. ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect. Immun. 2004, 72:6757-6763.
23. Gauduchon V., Cozon G., Vandenesch F., Genestier A.L., Eyssade N., Peyrol S., Etienne J., Lina G. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J. Infect. Dis. 2004, 189:346-353.
24. Gillet Y., Issartel B., Vanhems P., Fournet J.C., Lina G., Bes M., Vandenesch F., Piemont Y., Brousse N., Floret D., Etienne J. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359:753-759.
25. Gillet Y., Vanhems P., Lina G., Bes M., Vandenesch F., Floret D., Etienne J. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin. Infect. Dis. 2007, 45:315-321.
26. Gotz F. Staphylococcus and biofilms. Mol. Microbiol. 2002, 43:1367-1378.
27. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther. 2007, 7:1401-1413.
28. Jongerius I., Kohl J., Pandey M.K., Ruyken M., van Kessel K.P., van Strijp J.A., Rooijakkers S.H. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med. 2007, 204:2461-2471.
29. Jonsson G., Oxelius V.A., Truedsson L., Braconier J.H., Sturfelt G., Sjoholm A.G. Homozygosity for the IgG2 subclass allotype G2M(n) protects against severe infection in hereditary C2 deficiency. J. Immunol. 2006, 177:722-728.
30. Josefsson E., Hartford O., O'Brien L., Patti J.M., Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis. 2001, 184:1572-1580.
31. Kelly-Quintos C., Kropec A., Briggs S., Ordonez C.L., Goldmann D.A., Pier G.B. The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J. Infect. Dis. 2005, 192:2012-2019.
32. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H., Lynfield R., Dumyati G., Townes J.M., Craig A.S., Zell E.R., Fosheim G.E., McDougal L.K., Carey R.B., Fridkin S.K. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
33. Kluytmans J., van Belkum A., Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 1997, 10:505-520.
34. Kuklin N.A., Clark D.J., Secore S., Cook J., Cope L.D., McNeely T., Noble L., Brown M.J., Zorman J.K., Wang X.M., Pancari G., Fan H., Isett K., Burgess B., Bryan J., Brownlow M., George H., Meinz M., Liddell M.E., Kelly R., Schultz L., Montgomery D., Onishi J., Losada M., Martin M., Ebert T., Tan C.Y., Schofield T.L., Nagy E., Meineke A., Joyce J.G., Kurtz M.B., Caulfield M.J., Jansen K.U., McClements W., Anderson A.S. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 2006, 74:2215-2223.
35. LeClaire R.D., Hunt R.E., Bavari S. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect. Immun. 2002, 70:2278-2281.
36. Lee J.C., Park J.S., Shepherd S.E., Carey V., Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun. 1997, 65:4146-4151.
37. Lorenz U., Ohlsen K., Karch H., Hecker M., Thiede A., Hacker J. Human antibody response during sepsis against targets expressed by methicillin resistant Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 2000, 29:145-153.
38. Lowe A.M., Beattie D.T., Deresiewicz R.L. Identification of novel staphylococcal virulence genes by in vivo expression technology. Mol. Microbiol. 1998, 27:967-976.
39. Lowy F.D. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 2003, 111:1265-1273.
40. Maira-Litran T., Kropec A., Goldmann D., Pier G.B. Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide. Vaccine 2004, 22:872-879.
41. Maira-Litran T., Kropec A., Goldmann D.A., Pier G.B. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect. Immun. 2005, 73:6752-6762.
42. Mamo W., Fröman G., Müller H.P. Protection induced in mice vaccinated with recombinant collagen-binding protein (CnBP) and alpha-toxoid against intramammary infection with Staphylococcus aureus. Microbiol. Immunol. 2000, 44:381-384.
43. Matter L., Wilhelm J.A., Roth F., Schopfer K. Abnormal humoral immune response to Staphylococcus aureus in patients with Staphylococcus aureus hyper IgE syndrome. Clin. Exp. Immunol. 1986, 66:450-456.
44. McKenney D., Pouliot K.L., Wang Y., Murthy V., Ulrich M., Doring G., Lee J.C., Goldmann D.A., Pier G.B. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 1999, 284:1523-1527.
45. Mohamed N., Jones S.M., Casey L.S., Pincus S.E., Spitalny G.L. Heteropolymers: a novel technology against blood-borne infections. Curr. Opin. Mol. Ther. 2005, 7:144-150.
46. Moreillon P., Entenza J.M., Francioli P., McDevitt D., Foster T.J., Francois P., Vaudaux P. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect. Immun. 1995, 63:4738-4743.
47. Nemeth J., Lee J.C. Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis. Infect. Immun. 1995, 63:375-380.
48. Novick R.P. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol. Microbiol. 2003, 48:1429-1449.
49. Otto M. Targeted immunotherapy for staphylococcal infections: focus on anti-MSCRAMM antibodies. BioDrugs 2008, 22:27-36.
50. Pan Q., Hammarström L. Molecular basis of IgG subclass deficiency. Immunol. Rev. 2000, 178:99-110.
51. Park J., Jagasia R., Kaufmann G.F., Mathison J.C., Ruiz D.I., Moss J.A., Meijler M.M., Ulevitch R.J., Janda K.D. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem. Biol. 2007, 14:1119-1127.
52. Patti J.M. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 2004, 22(Suppl 1):S39-S43.
53. Pishchany G., Dickey S.E., Skaar E.P. Subcellular localization of the Staphylococcus aureus heme iron transport components IsdA and IsdB. Infect. Immun. 2009, 77:2624-2634.
54. Postma B., Poppelier M.J., van Galen J.C., Prossnitz E.R., van Strijp J.A., de Haas C.J., van Kessel K.P. Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J. Immunol. 2004, 172:6994-7001.
55. Projan S.J., Nesin M., Dunman P.M. Staphylococcal vaccines and immunotherapy: to dream the impossible dream?. Curr. Opin. Pharmacol. 2006, 6:473-479.
56. Ragle B.E., Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect. Immun. 2009, 77:2712-2718.
57. Rooijakkers S.H., Ruyken M., Roos A., Daha M.R., Presanis J.S., Sim R.B., van Wamel W.J., van Kessel K.P., van Strijp J.A. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 2005, 6:920-927.
58. Rooijakkers S.H., Ruyken M., van Roon J., van Kessel K.P., van Strijp J.A., van Wamel W.J. Early expression of SCIN and CHIPS drives instant immune evasion by Staphylococcus aureus. Cell. Microbiol. 2006, 8:1282-1293.
59. Rupp M.E., Holley H.P., Lutz J., Dicpinigaitis P.V., Woods C.W., Levine D.P., Veney N., Fowler V.G. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2007, 51:4249-4254.
60. Sarvas H., Rautonen N., Kayhty H., Kallio M., Makela O. Effect of Gm allotypes on IgG2 antibody responses and IgG2 concentrations in children and adults. Int. Immunol. 1990, 2:317-322.
61. Schaffer A.C., Solinga R.M., Cocchiaro J., Portoles M., Kiser K.B., Risley A., Randall S.M., Valtulina V., Speziale P., Walsh E., Foster T., Lee J.C. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect. Immun. 2006, 74:2145-2153.
62. Shinefield H., Black S., Fattom A., Horwith G., Rasgon S., Ordonez J., Yeoh H., Law D., Robbins J.B., Schneerson R., Muenz L., Fuller S., Johnson J., Fireman B., Alcorn H., Naso R. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 2002, 346:491-496.
63. Stoll B.J., Gordon T., Korones S.B., Shankaran S., Tyson J.E., Bauer C.R., Fanaroff A.A., Lemons J.A., Donovan E.F., Oh W., Stevenson D.K., Ehrenkranz R.A., Papile L.A., Verter J., Wright L.L. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J. Pediatr. 1996, 129:63-71.
64. Stranger-Jones Y.K., Bae T., Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16942-16947.
65. Therrien R., Lacasse P., Grondin G., Talbot B.G. Lack of protection of mice against Staphylococcus aureus despite a significant immune response to immunization with a DNA vaccine encoding collagen-binding protein. Vaccine 2007, 25:5053-5061.
66. Torres V.J., Pishchany G., Humayun M., Schneewind O., Skaar E.P. Staphylococcus aureus IsdB is a hemoglobin receptor required for heme iron utilization. J. Bacteriol. 2006, 188:8421-8429.
67. Verkaik N.J., de Vogel C.P., Boelens H.A., Grumann D., Hoogenboezem T., Vink C., Hooijkaas H., Foster T.J., Verbrugh H.A., van Belkum A., van Wamel W.J. Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus. J. Infect. Dis. 2009, 199:625-632.
68. Vernachio J.H., Bayer A.S., Ames B., Bryant D., Prater B.D., Syribeys P.J., Gorovits E.L., Patti J.M. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob. Agents Chemother. 2006, 50:511-518.
69. Visai L., Xu Y., Casolini F., Rindi S., Hook M., Speziale P. Monoclonal antibodies to CNA, a collagen-binding microbial surface component recognizing adhesive matrix molecules, detach Staphylococcus aureus from a collagen substrate. J. Biol. Chem. 2000, 275:39837-39845.
70. von Eiff C., Becker K., Machka K., Stammer H., Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 2001, 344:11-16.
71. Voyich J.M., Otto M., Mathema B., Braughton K.R., Whitney A.R., Welty D., Long R.D., Dorward D.W., Gardner D.J., Lina G., Kreiswirth B.N., DeLeo F.R. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?. J. Infect. Dis. 2006, 194:1761-1770.
72. Weems J.J., Steinberg J.P., Filler S., Baddley J.W., Corey G.R., Sampathkumar P., Winston L., John J.F., Kubin C.J., Talwani R., Moore T., Patti J.M., Hetherington S., Texter M., Wenzel E., Kelley V.A., Fowler V.G. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2006, 50:2751-2755.
73. Weisman L.E. Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature. Arch. Pediatr. 2007, 14(Suppl 1):S31-34.
74. Wertheim H.F., Vos M.C., Ott A., van Belkum A., Voss A., Kluytmans J.A., van Keulen P.H., Vandenbroucke-Grauls C.M., Meester M.H., Verbrugh H.A. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004, 364:703-705.
75. Zhou H., Xiong Z.Y., Li H.P., Zheng Y.L., Jiang Y.Q. An immunogenicity study of a newly fusion protein Cna-FnBP vaccinated against Staphylococcus aureus infections in a mice model. Vaccine 2006, 24:4830-4837.